Tracking of The Most Significant Laboratory Parameters For The Identification of Covid-19: An Overview on The Different Blood Tests

Abstract = 242 times | PDF = 89 times

Main Article Content

Seenaa Ali

Abstract

An outbreak of 2019 novel coronavirus disease (COVID-19) began in China during December 2019 which unexpectedly spread to other countries and caused high mortality all over the world. COVID-19 disease primarily manifests as a respiratory tract infection. However, emerging data indicate that it should be regarded as a systemic disease for affecting multiple systems such as cardiovascular, respiratory, gastrointestinal and immune system. There is an accelerated need for detecting the laboratory tests that can aid in identifying infected people and asymptomatic carriers to control the virus transmission process. Although the clinical manifestation of COVID-19 has been widely defined, an overview of the most significant laboratory findings in patients with COVID-19 infection is still limited. Elevation was the predominate result among most of the laboratory parameters while a few decreased in value. Laboratory data have shown that most patients had a decrease in lymphocyte count, Eosinophils count and albumin level. Also, laboratory data recorded an elevation in Leukocyte, ESR, PT, D-dimer, PCT, CRP, ALT, AST, Bilirubin, Creatinine, CK, LDH, Ferritin, Troponin, Myoglobin, IL-6, IL10 and TNF. In general, the parameters had more prominent laboratory abnormalities in severe cases than with non-severe cases. It is well known that laboratory tests results play an important role and can support the early diagnosis of many diseases. This study was carried out to review the abnormalities among the laboratory tests and track the parameters that showed a frequently significant result supporting the primary detection of SARS-COV-2 infection.

Keywords

COVID-19, SARC-COV2, 2019-nCoV, Laboratory parameters, Blood test

Downloads

Download data is not yet available.

Article Details

References

[1] World Health Organization, “WHO Timeline - COVID-19.” [Online]. Available: https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19. [Accessed: 29-May-2020].
[2] A. E. Gorbalenya et al., “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiol., vol. 5, no. 4, pp. 536–544, 2020.
[3] World Health Organization, “Naming the coronavirus disease (COVID-19) and the virus that causes it.” [Online]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it. [Accessed: 29-May-2020].
[4] N. Petrosillo, G. Viceconte, O. Ergonul, G. Ippolito, and E. Petersen, “COVID-19, SARS and MERS: are they closely related?,” Clin. Microbiol. Infect., vol. 26, no. 6, pp. 729–734, 2020.
[5] Iraq ministry of health, “الموقف الوبائي اليومي للإصابات بفيروس... - وزارة الصحة العراقية.” [Online]. Available: https://www.facebook.com/MOH.GOV.IQ/photos/a.860171854037214/2840429512678095/?type=3. [Accessed: 29-May-2020].
[6] Kurdistan regional government, “COVID-19: Situation Update - GOV.KRD.” [Online]. Available: https://gov.krd/coronavirus-en/situation-update/. [Accessed: 29-May-2020].
[7] Z. Chen et al., “From SARS-CoV to Wuhan 2019-nCoV: Will History Repeat Itself?,” bioRxiv. pp. 1–18, 2020.
[8] J. F. W. Chan et al., “A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster,” Lancet, vol. 395, no. 10223, pp. 514–523, 2020.
[9] Q. Li et al., “Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia,” N. Engl. J. Med., vol. 382, no. 13, pp. 1199–1207, 2020.
[10] World Health Organization, “Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.” [Online]. Available: https://www.who.int/publications-detail/laboratory-testing-for-2019-novel-coronavirus-in-suspected-human-cases-20200117. [Accessed: 29-May-2020].
[11] T. Ai et al., “Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases,” Radiology, 2020.
[12] X. Xie, Z. Zhong, W. Zhao, C. Zheng, F. Wang, and J. Liu, “Chest CT for Typical 2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing,” Radiology, 2020.
[13] D. Li et al., “False-negative results of real-time reverse-transcriptase polymerase chain reaction for severe acute respiratory syndrome coronavirus 2: Role of deep-learning-based ct diagnosis and insights from two cases,” Korean J. Radiol., vol. 21, no. 4, pp. 505–508, 2020.
[14] B. Cao, “Chinese Guideline of Diagnosis and treatment of COVID-19 Severe Acute Respiratory Syndrome Coronavirus-2.” pp. 1–30, 2020.
[15] Novel Coronavirus Pneumonia Emergency Response Epidemiology Team chinese center for disease control and prevention, “Vital surveillances: the epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020,” China CDC Wkly., vol. 41, no. 2, pp. 145–151, 2020.
[16] A. J. Rodriguez-Morales et al., “Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis,” Travel Med. Infect. Dis., vol. 34, pp. 1–13, 2020.
[17] G. Lippi and M. Plebani, “Laboratory abnormalities in patients with COVID-2019 infection,” Clinical Chemistry and Laboratory Medicine. pp. 1–4, 2020.
[18] L. Fu et al., “Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis,” J. Infect., vol. 80, no. 6, pp. 656–665, 2020.
[19] W. Guan et al., “Clinical characteristics of coronavirus disease 2019 in China,” N. Engl. J. Med., vol. 382, no. 18, pp. 1708–1720, 2020.
[20] C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” Lancet, vol. 395, no. 10223, pp. 497–506, 2020.
[21] L. Tan et al., “Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study,” Signal Transduct. Target. Ther., vol. 5, no. 33, pp. 1–3, 2020.
[22] Q. Li et al., “A simple laboratory parameter facilitates early identification of COVID-19 patients,” medRxiv. pp. 1–6, 2020.
[23] J. jin Zhang et al., “Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China,” Allergy: European Journal of Allergy and Clinical Immunology. pp. 1–12, 2020.
[24] Z. W. Weiliang Cao, Li Shi, Lin Chen, Xuemei Xu, “Clinical features and laboratory inspection of novel coronavirus pneumonia (COVID-19) in Xiangyang, Hubei,” medRxiv. pp. 1–13, 2020.
[25] D. Wang et al., “Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China,” JAMA - J. Am. Med. Assoc., vol. 323, no. 11, pp. 1061–1069, 2020.
[26] N. Chen et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” Lancet, vol. 395, no. 10223, pp. 507–513, 2020.
[27] J. Zhang, L. Zhou, Y. Yang, W. Peng, W. Wang, and X. Chen, “Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics,” Lancet Respir. Med., vol. 8, no. 3, pp. e1–e2, 2020.
[28] F. A. Lagunas-Rangel, “Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis,” Journal of Medical Virology. pp. 1–2, 2020.
[29] Y. Liu et al., “Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury,” Sci. China Life Sci., vol. 63, no. 3, pp. 364–374, 2020.
[30] A. Bastola et al., “The first 2019 novel coronavirus case in Nepal,” Lancet Infect. Dis., vol. 20, no. 3, pp. 279–280, 2020.
[31] G. Spiteri et al., “First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020,” Eurosurveillance, vol. 25, no. 9, pp. 1–6, 2020.
[32] W. K. Silverstein, L. Stroud, G. E. Cleghorn, and J. A. Leis, “First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia,” Lancet, vol. 395, no. 10223, p. 734, 2020.
[33] S. A. Kujawski et al., “Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States,” Nature Medicine. pp. 1–23, 2020.
[34] R. Mardani et al., “Laboratory Parameters in Detection of COVID-19 Patients with Positive RT-PCR; a Diagnostic Accuracy Study.,” Arch. Acad. Emerg. Med., vol. 8, no. 1, p. e43, 2020.
[35] A. Ahmed Hama, O. Abdulrahman Mohammed, F. Mahmud Ali, O. Hamid Shareef, S. Muhammad Wli, and S. Ahmed Qadir, “The Molecular Diagnosis Protocols of New Coronavirus (COVID-19); Specificity and Sensitivity an Overview,” Kurdistan J. Appl. Res., vol. 5, no. 3, pp. 13–22, 2020.
[36] World Health Organization, “Coronavirus disease (COVID-19) technical guidance: Laboratory testing for 2019-nCoV in humans.” [Online]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance. [Accessed: 29-May-2020].
[37] P. Zhou et al., “A pneumonia outbreak associated with a new coronavirus of probable bat origin,” Nature, vol. 579, no. 7798, pp. 270–273, 2020.
[38] S. L. Bai et al., “Analysis of the first cluster of cases in a family of novel coronavirus pneumonia in Gansu Province,” Zhonghua Yu Fang Yi Xue Za Zhi, vol. 54, pp. 1–4, 2020.
[39] S. Y. Xiao, Y. Wu, and H. Liu, “Evolving status of the 2019 novel coronavirus infection: Proposal of conventional serologic assays for disease diagnosis and infection monitoring,” J. Med. Virol., vol. 92, no. 5, pp. 464–467, 2020.
[40] Centers for Disease Control and Prevention, “Serology Testing for COVID-19 at CDC.” [Online]. Available: https://www.cdc.gov/coronavirus/2019-ncov/lab/serology-testing.html. [Accessed: 29-May-2020].
[41] U.S. Food and Drug Administration, “Coronavirus (COVID-19) Update: Serological Tests.” [Online]. Available: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-serological-tests. [Accessed: 29-May-2020].
[42] Z. Wu and J. M. McGoogan, “Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China,” JAMA, vol. 323, no. 13, pp. 1239–1242, 2020.
[43] X. Xu et al., “Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2,” Eur. J. Nucl. Med. Mol. Imaging, vol. 47, no. 5, pp. 1275–1280, 2020.
[44] Y. Fang et al., “Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR,” Radiology. pp. 1–8, 2020.
[45] M.-Y. Ng et al., “Imaging Profile of the COVID-19 Infection: Radiologic Findings and Literature Review,” Radiol. Cardiothorac. Imaging, vol. 2, no. 1, pp. 1–26, 2020.
[46] H. Y. F. Wong et al., “Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients,” Radiology. pp. 1–23, 2019.
[47] Centers for Disease Control and Prevention, “CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel.” pp. 1–53, 2020.
[48] D. Ferrari, A. Motta, M. Strollo, G. Banfi, and M. Locatelli, “Routine blood tests as a potential diagnostic tool for COVID-19,” Clinical Chemistry and Laboratory Medicine. pp. 1–5, 2020.